Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;236:108961. doi: 10.1016/j.clim.2022.108961

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — Vaccine-induced SARS-CoV-2-specific IL-2- and IFN-γ-producing T cells and SARS-CoV-2 anti-spike IgG antibodies as determined using the GenID assay at T1 and T2, stratified by mRNA vaccine regimen (A–C), vector-based vaccine regimen (D—F), for infection naïve patients, or booster vaccination in patients with a history of SARS-CoV-2 infection (G–I).

A) IL-2: T1 (n = 37): Not reactive, 17 (45.9%); borderline, 6 (16.2%); reactive, 12 (32.4%); invalid, 2 (5.4%). T2 (n = 44): Not reactive, 17 (38.6%); borderline, 4 (9.1%); reactive, 11 (25.0%); invalid, 12 (27.3%).

B) IFN-γ: T1 (n = 37): Not reactive, 32 (86.5%); borderline, 0 (0%); reactive, 4 (10.8%); invalid, 1 (2.7%). T2 (n = 44): Not reactive, 30 (68.1%); borderline, 2 (4.5%); reactive, 9 (20.5%); invalid, 3 (6.8%).

C) IgG: T1 (n = 37): Positive, 32 (86.5%)^a; negative, 5 (13.5%)^b. T2 (n = 44): Positive, 39 (88.6%)^a; negative, 5 (11.4%)^b.

D) IL-2: T1 (n = 7): Not reactive, 3 (42.9%); borderline, 0 (0%); reactive, 1 (14.3%); invalid, 3 (42.9%). T2 (n = 9): Not reactive, 3 (33.3%); borderline, 1 (11.1%); reactive, 1 (11.1%); invalid, 4 (44.4%).

E) IFN-γ: T1 (n = 7): Not reactive, 5 (71.4%); borderline, 0 (0%); reactive, 1 (14.3%); invalid, 1 (14.3%). T2 (n = 9): Not reactive, 4 (44.4%); borderline, 1 (11.1%); reactive, 1 (11.1%); invalid, 3 (44.4%).

F) IgG: T1 (n = 7): Positive, 6 (85.7%)^a; negative, 1 (14.3%)^b. T2 (n = 9): Positive, 8 (88.9%)^a; negative, 1 (11.1%)^b.

G) IL-2: T1 (n = 6): Not reactive, 1 (16.7%); borderline, 0 (0%); reactive, 5 (83.3%); invalid, 0 (0%). T2 (n = 5): Not reactive, 1 (20.0%); borderline, 1 (20.0%); reactive, 3 (60.0%); invalid, 0 (0%).

H) IFN-γ: T1 (n = 6): Not reactive, 0 (0%); borderline, 0 (0%); reactive, 6 (100%); invalid, 0 (0%). T2 (n = 5): Not reactive, 0 (0%); borderline, 1 (20.0%); reactive, 4 (80.0%); invalid, 0 (0%).

I) IgG: T1 (n = 6): Positive, 6 (100%)^a; negative, 0 (0%)^b. T2 (n = 5): Positive, 5 (100%)^a; negative 0 (0%)^b.

All individuals with a history of SARS-CoV-2 infection were vaccinated with one dose of mRNA- BNT162b2 (n = 6).

The dashed horizontal lines indicate the cut-off for positivity (reactive); the area between the horizontal lines indicates the borderline zone used in each GenID assay.

^aPositive refers to antibody levels >16%.

^bNegative refers to antibody levels ≤16%.

IgG, immunoglobulin G; IFN-γ, interferon-γ; IL-2, interleukin-2.